Skip to content
Peptide Evidence Registry

GLP-1s & incretins · Metabolic & endocrine

EloraTZP

An experimental combination of the amylin receptor agonist eloralintide with tirzepatide, studied as a combination rather than a single new molecule.

L3Early human studiesIn clinical trialsIn clinical development
How settled this rating is:
moderate confidence in the current evidence rating
Routes studied:
Subcutaneous injection
Also known as:
eloralintide + tirzepatide combination
Last reviewed:
2026-10-01
Jump to section

Evidence passport

EloraTZP

A one-screen evidence identity for this compound. These fields describe research maturity, confidence and legal status. They are not a safety guarantee, efficacy percentage or recommendation.

Reviewed 2026-10-01
Evidence level
L3Early human studies
Confidence
Moderate confidence in rating
Regulatory status
In clinical trials
Development status
In clinical development

Evidence strength

Human efficacy evidence55 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Human safety evidence30 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

The 0-100 values rate the strength and maturity of evidence, not how effective or safe the compound is.

Evidence base
Includes human studies
Furthest established stage
Phase II
Human research maturity
Phase 2b controlled human efficacy data presented at EASD 2026; Phase 3 planned for Q4 2026
Source curation
Sources fully curated

Routes recorded

SC injection

Overview

Human efficacy evidence strength55 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Preclinical (animal / lab) evidence strength40 of 100 evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Human safety evidence strength30 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

How far human research has progressed: Phase 2b controlled human efficacy data presented at EASD 2026; Phase 3 planned for Q4 2026

Routes & formulations

Studied / approved routes

SC injection

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

    Furthest established stage

  5. Phase III

  6. Approved

In clinical development

Filed as a combination record. A 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes reported controlled efficacy results at EASD 2026. Lilly plans Phase 3 initiation in Q4 2026. The combination remains investigational.

Last documented development: 30 September 2026 — Phase 2b results presented at EASD; Phase 3 planned for Q4 2026

What it is

Two distinct drugs used together: eloralintide, an amylin receptor agonist, and tirzepatide, a GLP-1/GIP dual agonist. It is a combination, not a unimolecular triple agonist.

What people claim

  • More weight loss than tirzepatide alone
  • The new standard of care

What the evidence actually says

Controlled Phase 2b results now support greater average weight loss and A1C reduction for several EloraTZP regimens versus tirzepatide 15 mg in the studied population. At 48 weeks, the strongest reported regimen averaged 23.3% weight loss versus 14.8% with tirzepatide 15 mg, with A1C reduction up to 2.9% versus 2.4%. These are sponsor-reported Phase 2b results in adults with obesity or overweight and type 2 diabetes, not evidence of approval or superiority in routine care. Phase 3 is planned.

Related evidence

Useful next reads based on this compound — not recommendations.

Human evidence

  • Phase 2b (367 adults with obesity or overweight and type 2 diabetes, 48 weeks): Lilly reported average weight loss up to 23.3% with EloraTZP versus 14.8% with tirzepatide 15 mg.
  • The same trial reported A1C reduction up to 2.9% with EloraTZP versus 2.4% with tirzepatide 15 mg. Phase 3 is planned for Q4 2026; the combination remains investigational.

Preclinical evidence

  • Amylin plus incretin pharmacology is an actively explored combination approach preclinically; molecule-specific preclinical detail for this pairing is not established in our record.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

Combination of separate drugsTwo or more distinct molecules given together or co-formulated. Evidence for either component alone is not evidence for the combination.

Receptor targets: Amylin receptor, GLP-1 receptor, GIP receptor

Mechanism class counts the receptors the pharmacology engages and says whether one molecule or several drugs do it. More targets is not the same as more effective, and none of these labels is a receptor name — there is no GLP-3, GLP-4 or GLP-5 receptor.

  • Tirzepatide provides GLP-1 and GIP receptor agonism.
  • Eloralintide adds amylin receptor agonism, a separate satiety pathway.
  • Two pathways may be additive, less than additive, or worse tolerated together. That is an empirical question, not something the mechanism answers.

Safety and unknowns

  • Phase 2b provides initial controlled combination safety data, but longer and larger Phase 3 safety data are still needed. Gastrointestinal effects remain an important class consideration.
  • Nothing here supports combining medicines outside a clinical trial or clinical care.

Cancer relevance

This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.

Monitored in trials; not demonstrated in humans

Not established for the combination. Class-level incretin considerations from the tirzepatide component apply.

Regulatory status

Regulatory decisions apply to specific jurisdictions, products, formulations and indications. An approval elsewhere is not automatically an approval in your country.

Check the regulatory note and linked primary sources for jurisdiction-specific details.

Not approved as a combination anywhere. Tirzepatide is separately approved in its own right; that approval does not extend to this combination, which has to be established on its own evidence.

Evidence grade

L3Early human studiesModerate confidence in rating

Preliminary human outcome research, including small or observational studies. Descriptive exposure studies alone do not demonstrate therapeutic benefit.

What would change our rating?

  • Peer-reviewed publication of the Phase 2b dataset and replication in Phase 3.
  • Completed Phase 3 efficacy and longer-term safety results.
  • Any regulatory submission for the combination.

References and sources

Source transparency

A provenance snapshot of this profile. Counts show what kinds of sources are cited, not how much scientific weight each source deserves.

Sources fully curated
Last editorial review
2026-10-01
Recently reviewed · 15 days ago
Linked curated sources
2
Sources still pending
0
External specialist reviews
0
None recorded for this profile
Sponsor / official: 2

Review provenance

Registry editorial review: Colin Jackson-White, creator and editor, who is not a doctor or clinician. External specialist review is credited only when a named reviewer has completed a review of this exact profile.

Current linked evidence is sponsor-only. Treat findings as provisional until independent or peer-reviewed documentation is available.

Literature-discovery and AI tools may help locate or challenge candidate evidence, but they are not counted as evidence sources here. Registry judgements are tied to the underlying papers, trial records, regulator documents and official study records.

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

These entries record changes to our assessment of the published evidence — not changes to the compound itself.

No recorded changes yet. Baseline position set on 2026-10-01.